Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food and Drug Administration Drug Development Tool (DDT) Research Grant to ...

“We need future studies to help us understand the relationship between cholesterol variability and dementia risk,” she said ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

Investors included Techstars, Jinqiu Capital, MiraclePlus, Hat-trick... at 12:20 Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development Perspectum, a leader in ...

VacSYn is an adaptive, placebo-controlled, and biomarker-based Phase 2 study in patients with early PD, consisting of two ...

Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

Explore how the platelet-to-albumin ratio correlates with disease activity in early rheumatoid arthritis, potentially serving ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...

suggesting the accumulation of antibodies as an aging hallmark and the potential of IgG as a biomarker of aging. In human and ...

It's the third prize sponsored by the Richard King Mellon Foundation. A team studying a link between obesity and high-risk ...

These are exciting and transformational times for Chemomab,” said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief ...